Hypermetabolism and altered substrate oxidation in HIV-infected patients with lipodystrophy

Nutrition

Volumn 28, Issue 9, 2012, Pages 912-916

  Vassimon, Helena S ^a   de Paula, Francisco José Albuquerque ^a   Machado, Alcyone A ^a   Monteiro, Jacqueline P ^a   Jordão, Alceu A ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Carbohydrate oxidation; Energy expenditure; HIV; Indirect calorimetry; Lipodystrophy

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; BODY COMPOSITION; CALORIC INTAKE; CALORIMETRY; CARBOHYDRATE METABOLISM; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIET RESTRICTION; DUAL ENERGY X RAY ABSORPTIOMETRY; ENERGY EXPENDITURE; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERMETABOLISM; INDIRECT CALORIMETRY; LEAN BODY WEIGHT; LIPID OXIDATION; MALE; OBSERVATIONAL STUDY; OXIDATION; PRIORITY JOURNAL; SUBSTRATE OXIDATION; VIRUS LOAD;

ADULT; BREAKFAST; DIETARY CARBOHYDRATES; DIETARY FATS; ENERGY METABOLISM; FASTING; HIV INFECTIONS; HIV-1; HUMANS; LIPODYSTROPHY; MALE; MIDDLE AGED; OXIDATION-REDUCTION; POSTPRANDIAL PERIOD;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84864517955     PISSN: 08999007     EISSN: 18731244     Source Type: Journal    
DOI: 10.1016/j.nut.2011.12.010     Document Type: Article

References (29)

1. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010, 50:1387-1396. Antiretroviral Therapy Cohort Collaboration.
2. Ye Y., Zeng Y., Li X., Zhang S., Fang Q., Luo L., et al. HIV infection: an independent risk factor of peripheral arterial disease. J Acquir Immune Defic Syndr 2010, 53:276-278.
3. Capeau J. From lipodystrophy and insulin resistance to metabolic syndrome: HIV infection, treatment and aging. Curr Opin HIV AIDS 2007, 2:247-252.
4. Balasubramanyam A., Sekhar R.V., Jahoor F., Pownall H.J., Lewis D. Pathophysiology of adipocyte defects and dyslipidemia in HIV lipodystrophy: New evidence from metabolic and molecular studies. Am J Infect Dis 2006, 2:167-172.
5. Rogge M.M. The role of impaired mitochondrial lipid oxidation in obesity. Biol Res Nurs 2009, 4:356-373.
6. Pannacciulli N., Salbe A.D., Ortega E., Venti C.A., Bogardus C., Krakoff J. The 24-h carbohydrate oxidation rate in a human respiratory chamber predicts ad libitum food intake. Am J Clin Nutr 2007, 86:625-632.
7. Kosmiski L.A., Kuritzkes D.R., Sharp T.A., Hamilton J.T., Lichtenstein K.A., Mosca C.L., et al. Total energy expenditure and carbohydrate oxidation are increased in the human immunodeficiency virus lipodystrophy syndrome. Metabolism 2003, 52:620-625.
8. Luzi L., Perseghin G., Tambussi G., Meneghini E., Scifo P., Pagliato E., et al. Intramyocellular lipid accumulation and reduced whole body lipid oxidation in HIV lipodystrophy. Am J Physiol Endocrinol Metab 2003, 284:E274-E280.
9. Sutinen J., Yki-Jarvinen H. Increased resting energy expenditure, fat oxidation, and food intake in patients with highly active antiretroviral therapy-associated lipodystrophy. Am J Physiol Endocrinol Metab 2007, 292:E687-E692.
10. Kosmiski L.A., Bessesen D.H., Stotz S.A., Koeppe J.R., Horton T.J. Short-term energy restriction reduces resting energy expenditure in patients with HIV lipodystrophy and hypermetabolism. Metabolism 2007, 56:289-295.
11. Kosmiski L.A., Kuritzkes D.R., Lichtenstein K.A., Glueck D.H., Gourley P.J., Stamm E.R., et al. Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome. Aids 2001, 15:1993-2000.
12. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
13. Weir J.B. New methods for calculating metabolic rate with special reference to protein metabolism. J Physiol 1949, 109:1-9.
14. Schutz Y. The basis of direct and indirect calorimetry and their potentials. Diabetes Metab Rev 1995, 11:383-408.
15. Jequier E. Measurement of energy expenditure in clinical nutritional assessment. JPEN J Parenter Enteral Nutr 1987, 11:86S-89S.
16. Batterham M.J. Investigating heterogeneity in studies of resting energy expenditure in persons with HIV/AIDS: a meta-analysis. Am J Clin Nutr 2005, 81:702-713.
17. Kosmiski L.A., Ringham B.M., Grunwald G.K., Bessesen D.H. Dual-energy X-ray absorptiometry modeling to explain the increased resting energy expenditure associated with the HIV lipoatrophy syndrome. Am J Clin Nutr 2009, 90:1525-1531.
18. Kosmiski L., Kuritzkes D., Hamilton J., Sharp T., Lichtenstien K., Hill J., et al. Fat distribution is altered in HIV-infected men without clinical evidence of the HIV lipodystrophy syndrome. HIV Med 2003, 4:235-240.
19. Kelley D.E., Mandarino L.J. Fuel selection in human skeletal muscle in insulin resistance: a reexamination. Diabetes 2000, 49:677-683.
20. Van Wijk J.P., Cabezas M.C. Hypertriglyceridemia, metabolic syndrome, and cardiovascular disease in HIV-infected patients: effects of antiretroviral therapy and adipose tissue distribution. Int J Vasc Med 2012, 2012:201027.
21. Haugaard S.B., Andersen O., Pedersen S.B., Dela F., Fenger M., Richelsen B., et al. Tumor necrosis factor alpha is associated with insulin-mediated suppression of free fatty acids and net lipid oxidation in HIV-infected patients with lipodystrophy. Metabolism 2006, 55:175-182.
22. Silva M.M., Simoes R.T., Castelli E.C., Mendes-Junior C.T., Deghaide N.H., Tsuda L.C., et al. TNF microsatellite alleles may confer protection against the development of lipodystrophy syndrome in Brazilian HIV patients. Int J Immunogenet 2010, 37:379-385.
23. Veloso S., Olona M., Peraire J., Vilades C., Pardo P., Domingo P., et al. No relationship between TNF-alpha genetic variants and combination antiretroviral therapy-related lipodystrophy syndrome in HIV type 1-infected patients: a case-control study and a meta-analysis. AIDS Res Hum Retroviruses 2011, 27:143-152.
24. Randle P.J., Garland P.B., Hales C.N., Newsholme E.A. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963, 1:785-789.
25. Kelley D.E., Goodpaster B.H. Skeletal muscle triglyceride. An aspect of regional adiposity and insulin resistance. Diabetes Care 2001, 24:933-941.
26. Galgani J.E., Moro C., Ravussin E. Metabolic flexibility and insulin resistance. Am J Physiol Endocrinol Metab 2008, 295:E1009-E1017.
27. Kelley D.E. Skeletal muscle fat oxidation: timing and flexibility are everything. J Clin Invest 2005, 115:1699-1702.
28. Corpeleijn E., Mensink M., Kooi M.E., Roekaerts P.M., Saris W.H., Blaak E.E. Impaired skeletal muscle substrate oxidation in glucose-intolerant men improves after weight loss. Obesity 2008, 16:1025-1032.
29. Kotronen A., Seppala-Lindroos A., Vehkavaara S., Bergholm R., Frayn K.N., Fielding B.A., et al. Liver fat and lipid oxidation in humans. Liver Int 2009, 29:1439-1446.